Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 332 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | June 27, 2015

Is it Time for this Biotech to Change Management?

With Aegerion Pharmaceuticals down 500% from its all-time high, the current CEO's tenure is trying investors' patience.

Investing | June 11, 2015

3 Things AbbVie Inc.'s Management Wants You to Know

AbbVie's management team had a lot to talk about on their last investor conference call. Here are my three takeaways you need to know when considering the stock for investment.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 10, 2015

Cancer Stocks: 2 to Sell, 1 to Buy

Advaxis, Ariad Pharmaceuticals, and Exelixis Inc. are three cancer fight companies that could generate out-sized gains for investors. A deeper look, however, suggests that only one company is a compelling buy right now.

Investing | June 07, 2015

Cancer Drugs: 2 Stocks to Watch

AstraZeneca and Agenus Inc. are paving the way for a new generation of breakthrough cancer drugs that boost the immune system's ability to detect and eradicate malignancies. Here's what investors need to know about these two biopharmas going forward.

Investing | May 31, 2015

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Investing | May 30, 2015

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Amgen has shelved its once-promising psoriasis drug. Should investors worry?

Investing | May 28, 2015

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

Investing | May 21, 2015

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?

Investing | May 10, 2015

Investors Just Doubled Their Money on This Stock

Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.

Results 1 - 10 of 332 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology